Welcome to our dedicated page for Abivax S.A. news (Ticker: ABVX), a resource for investors and traders seeking the latest updates and insights on Abivax S.A. stock.
Abivax SA (ABVX) generates frequent news flow as a clinical-stage biotechnology company advancing obefazimod (ABX464) for chronic inflammatory diseases, particularly inflammatory bowel disease. Company press releases focus on clinical trial milestones, scientific presentations, financial updates, and capital markets developments related to its programs in ulcerative colitis and Crohn’s disease.
Investors and observers following ABVX news can expect detailed updates on the ABTECT Phase 3 program in moderately to severely active ulcerative colitis, including induction and maintenance trial results, Data Safety Monitoring Board reviews, and analyses of efficacy, safety, and patient-reported outcomes. News items also cover the ENHANCE-CD Phase 2b induction trial in moderate-to-severely active Crohn’s disease and preclinical work on obefazimod’s anti-fibrotic activity in inflammatory bowel disease models.
Abivax regularly announces the acceptance and presentation of late-breaking abstracts and multiple scientific posters at major meetings such as the United European Gastroenterology (UEG) Congress and the European Crohn’s and Colitis Organization (ECCO) Congress. These news releases describe new clinical subgroup analyses, biomarker data, and quality-of-life outcomes, as well as symposia and educational events organized by the company.
On the corporate side, Abivax news includes financial results, descriptions of research and development spending, and information on equity offerings and index inclusions, such as admission to the CAC Mid 60, SBF 120, and Nasdaq Biotechnology Index. Together, these updates provide a view of how Abivax is progressing its lead asset obefazimod, managing its financial resources, and positioning itself within the biotechnology sector. Bookmark this page to review the latest ABVX press releases, clinical data announcements, and regulatory and capital markets communications in one place.
Abivax has announced initial preclinical combination data of obefazimod and etrasimod in an inflammatory bowel disease (IBD) mouse model. The company is conducting studies with multiple oral and injectable therapies, with additional data expected in Q4 2024. The preclinical evaluation showed improved body weight protection and Disease Activity Index, with a synergistic and statistically significant reduction of several cytokines compared to individual treatments.
Abivax aims to develop a fixed-dose combination therapy for ulcerative colitis (UC) patients, targeting best-in-disease state induction and maintenance efficacy. The company believes obefazimod's safety and efficacy profile makes it an attractive candidate for combination with other mechanisms of action. Abivax plans to select a candidate in 2025 and develop a fixed-dose combination for clinical development.
Abivax SA (ABVX) has released its first-half 2024 financial results, highlighting a cash balance of EUR 222.3M as of June 30, 2024, with a cash runway extending into Q4 2025. The company reported an increased operating loss of EUR 80.0M, up from EUR 37.3M in the same period of 2023. This increase was primarily driven by higher R&D expenses, which rose to EUR 64.7M, mainly due to the progression of Phase 3 clinical trials for obefazimod in Ulcerative Colitis. Sales and marketing expenses increased to EUR 4.2M, while general and administrative costs rose to EUR 17.9M. The company's net loss for the period was EUR 81.6M, compared to EUR 52.0M in H1 2023. Abivax also completed drawdowns of tranches B and C of the Kreos/Claret financing, each for EUR 25M.
Abivax (ABVX) has reached a significant milestone in its Phase 3 ABTECT trial for obefazimod, a treatment for moderately to severely active ulcerative colitis (UC). The trial has surpassed 600 enrolled patients, keeping it on track to achieve full enrollment by early Q1 2025. This progress aligns with the company's expectations and reflects similar baseline characteristics and trends observed in the earlier Phase 2b trial.
The ABTECT trial is a important step in Abivax's development of therapeutics that aim to stabilize the immune response in chronic inflammatory diseases. The company's approach focuses on harnessing the body's natural regulatory mechanisms. With this enrollment milestone, Abivax reaffirms its timeline for the trial's completion, potentially bringing obefazimod closer to market for UC patients.
Abivax SA (ABVX) provided an update on its key clinical programs and leadership changes. The Phase 3 ABTECT trial for obefazimod in ulcerative colitis is on track to complete enrollment in early Q1 2025, with top-line results expected in early Q2 2025. The company is making progress on its pre-clinical combination therapy program. Sylvie Grégoire has been named Chair of Abivax's Board of Directors, while Dr. Fabio Cataldi and Dr. David Zhang have been appointed as Chief Medical Officer and Chief Strategy Officer, respectively.
Abivax's cash position allows for runway into Q4 2025, covering the ABTECT 8-week induction top-line results. The company is focusing on R&D while streamlining G&A expenses. The Phase 2b ENHANCE-CD trial for Crohn's disease is planned to start enrollment in September 2024.
Abivax SA, a clinical-stage biotechnology company, announced the results of its Ordinary and Extraordinary General Meeting held on May 30, 2024.
The shareholders approved all resolutions proposed by the Board, including the financial statements for 2023, the compensation policy for top executives, and delegations related to financial transactions.
New Board members, Mr. Troy Ignelzi, Dr. June Lee, and Ms. Camilla Soenderby, were ratified.
Details of the vote results can be accessed on the company's website.
Summary not available.
Summary not available.
Summary not available.